Does UnitedHealthcare Cover Eliquis?

UnitedHealthcare Formulary Placement for Eliquis

Most UnitedHealthcare plans include Eliquis (apixaban) on their prescription drug formulary, though the specific tier placement varies by plan type. On commercial and employer-sponsored plans, Eliquis generally falls on Tier 3 as a preferred brand-name medication. On certain Medicare Advantage and exchange plans, it may appear on Tier 4 as a non-preferred brand.

How Tier Placement Affects Your Cost

Tier placement directly determines your copay or coinsurance. A Tier 3 designation on a typical UHC commercial plan means a fixed copay between $35 and $75 per 30-day supply. Tier 4 placement shifts the cost structure toward coinsurance, often 25% to 33% of the drug's retail price [1]. Since the wholesale acquisition cost of Eliquis runs approximately $580 to $620 per month, a 30% coinsurance rate can push out-of-pocket costs above $170 before any copay assistance.

Checking Your Specific Plan

The fastest way to confirm your tier is to log into myuhc.com and search "apixaban" or "Eliquis" in the formulary lookup tool. Every UHC member ID card lists a plan code that maps to a specific formulary document. Your employer's benefits coordinator can also provide the Summary of Benefits and Coverage (SBC), which lists drug tier structures and any quantity limits [2].

Prior Authorization and Step Therapy Requirements

UnitedHealthcare does not require prior authorization for Eliquis on every plan. Commercial PPO and HMO plans with broad formularies often allow prescribers to write Eliquis without preapproval. Medicare Advantage plans, by contrast, more frequently attach a prior authorization requirement or a step therapy protocol.

What Step Therapy Looks Like

Step therapy (sometimes called "fail-first") means UHC requires documentation that a lower-cost anticoagulant, typically warfarin, was tried and either failed to control the condition, caused adverse effects, or is clinically inappropriate for the patient. The American College of Cardiology (ACC) and American Heart Association (AHA) 2019 Focused Update on atrial fibrillation management lists direct oral anticoagulants (DOACs) like apixaban as a Class I recommendation over warfarin for most patients with non-valvular atrial fibrillation, citing lower rates of intracranial hemorrhage [3].

How to Handle a Denial

If UHC denies Eliquis coverage, your prescriber can submit a prior authorization form with clinical justification. Strong justification includes documented warfarin intolerance, labile INR values, CHA2DS2-VASc score of 2 or higher, or a HAS-BLED score indicating elevated bleeding risk. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced the rate of stroke or systemic embolism by 21% compared to warfarin (1.27% vs. 1.60% per year, P<0.001 for noninferiority, P=0.01 for superiority), with a 31% reduction in major bleeding [4]. Citing this data in the appeal letter strengthens the clinical case considerably.

What Eliquis Costs on UnitedHealthcare Plans

Out-of-pocket cost depends on three variables: your plan's tier and copay structure, whether you qualify for manufacturer copay assistance, and which phase of coverage you occupy if on Medicare Part D.

Commercial Plan Costs

On commercial UHC plans with Tier 3 placement, expect a flat copay between $35 and $75 per month. Plans with coinsurance rather than copays will charge a percentage of the negotiated rate, which is lower than the retail price but still significant. Bristol-Myers Squibb and Pfizer offer the Eliquis 360 Support copay card for commercially insured patients. Eligible patients can reduce their copay to as low as $10 per month, with a maximum annual benefit of approximately $6,400 [5].

Medicare Part D Costs

Medicare Part D plans follow a defined benefit structure. During the initial coverage phase, you pay your plan's copay or coinsurance. Once total drug spending crosses the coverage gap threshold ($5,030 in 2025), you enter the so-called "donut hole" where you pay 25% of the drug cost until catastrophic coverage begins at $8,000 in true out-of-pocket spending [6]. Eliquis is expensive enough that patients taking it year-round often reach the coverage gap by mid-year.

The manufacturer copay card does not apply to Medicare, Medicaid, or other federal healthcare program beneficiaries. Medicare patients looking to reduce costs should explore Extra Help (Low-Income Subsidy) through the Social Security Administration, which can reduce copays to $4.50 to $11.20 per prescription for qualifying individuals [7].

Comparing Costs Across UHC Plan Types

A 2023 analysis published in the Journal of the American Heart Association found that among commercially insured patients prescribed DOACs, median annual out-of-pocket spending on apixaban was $492, though the top quartile paid more than $1,200 annually [8]. UHC members on high-deductible health plans (HDHPs) face full retail pricing until meeting their deductible, which can mean paying $580 or more for the first few fills.

FDA-Approved Indications That UHC Will Cover

UnitedHealthcare covers Eliquis for its FDA-approved indications. Off-label use generally requires additional clinical documentation and may be denied.

Stroke Prevention in Non-Valvular Atrial Fibrillation

This is the most common reason Eliquis is prescribed. The FDA approved apixaban in December 2012 for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, based on the ARISTOTLE trial data [4]. Approximately 6.1 million Americans live with atrial fibrillation, according to CDC estimates [9]. UHC routinely covers Eliquis for this indication, especially when the prescriber documents a CHA2DS2-VASc score supporting anticoagulation.

Treatment of DVT and Pulmonary Embolism

The AMPLIFY trial (N=5,395) showed that apixaban was noninferior to standard enoxaparin-warfarin therapy for recurrent VTE (2.3% vs. 2.7%) while causing significantly less major bleeding (0.6% vs. 1.8%, P<0.001) [10]. UHC covers Eliquis for acute DVT and PE treatment, typically for an initial 6-month course with potential extension based on clinical need.

VTE Prophylaxis After Hip or Knee Replacement

The ADVANCE-2 and ADVANCE-3 trials established apixaban's efficacy for preventing venous thromboembolism after elective knee and hip replacement surgery [11]. UHC covers short-course Eliquis (10 to 35 days) following these procedures. Coverage is straightforward for this indication because the duration is limited and the clinical evidence is well-established.

How Eliquis Compares to Other Anticoagulants on UHC Formularies

UnitedHealthcare formularies typically include multiple anticoagulant options across different tiers. Understanding the field helps you and your prescriber choose the most clinically appropriate and cost-effective option.

Warfarin

Generic warfarin sits on Tier 1 across virtually all UHC plans, with copays of $0 to $15 per month. It remains effective but requires regular INR monitoring, dietary restrictions, and carries a higher risk of intracranial hemorrhage compared to DOACs. The 2019 AHA/ACC/HRS guideline states: "DOACs are recommended over warfarin in DOAC-eligible patients with AF" (Class I, Level of Evidence A) [3].

Xarelto (Rivaroxaban)

Xarelto typically occupies the same tier as Eliquis on UHC formularies (Tier 3 or Tier 4). The ROCKET AF trial (N=14,264) demonstrated rivaroxaban's noninferiority to warfarin for stroke prevention in AF, though it did not achieve superiority for the primary endpoint in the intention-to-treat analysis [12]. Some UHC plans may prefer one DOAC over the other based on rebate negotiations with manufacturers.

Savaysa (Edoxaban) and Pradaxa (Dabigatran)

These older DOACs sometimes appear on lower tiers. Pradaxa (dabigatran) was the first FDA-approved DOAC, validated in the RE-LY trial (N=18,113), which showed reduced stroke rates versus warfarin at the 150 mg dose [13]. Savaysa is less commonly prescribed. If UHC denies Eliquis, your prescriber might consider these alternatives, though each has distinct dosing requirements and a different drug interaction profile.

Tips for Getting Eliquis Covered and Reducing Your Cost

Patients and prescribers can take specific steps to maximize coverage approval and minimize out-of-pocket spending.

Use the Manufacturer Copay Card

If you have commercial insurance (not Medicare, Medicaid, or Tricare), enroll in the Eliquis 360 Support program. The copay card covers the difference between your plan's copay and the $10 patient cost, up to the annual maximum [5]. Enrollment is free and can be done online or by phone.

Request a Formulary Exception

If Eliquis is on a higher tier, your prescriber can submit a formulary exception request to UHC, asking that it be covered at a lower tier. The request must include clinical rationale explaining why Eliquis is medically necessary over lower-tier alternatives. A 2021 study in Health Affairs found that approximately 60% of formulary exception requests for DOACs were approved when accompanied by documentation of warfarin contraindications or intolerance [14].

Consider a 90-Day Mail-Order Supply

UHC's OptumRx mail-order pharmacy often offers a 90-day supply at a lower per-unit cost than three separate 30-day retail fills. The savings can be 10% to 25% depending on your plan. Log into optumrx.com or call the number on your member ID card to check pricing.

Time Your Coverage Gap Strategy

For Medicare Part D members, front-loading a 90-day supply early in the year and using patient assistance programs can help manage the coverage gap. Some patients coordinate with their prescriber to use manufacturer samples during the gap period, though availability varies.

When UnitedHealthcare Might Not Cover Eliquis

Coverage is not guaranteed in every scenario. Understanding the common exceptions helps you plan ahead.

Off-Label Use

Prescribing Eliquis for conditions outside its FDA-approved indications (for example, left ventricular thrombus without AF, or antiphospholipid syndrome) may trigger a denial. The TRAPS trial was stopped early after finding that rivaroxaban was inferior to warfarin for antiphospholipid syndrome, raising concerns about all DOACs in this population [15]. UHC generally follows FDA labeling for coverage decisions on brand-name drugs.

Plan Exclusions

Some narrow-network or limited formulary plans exclude certain brand-name medications entirely. Short-term health insurance plans and health-sharing ministries marketed through UHC affiliates may not cover prescription drugs at all. Always verify formulary inclusion before filling a prescription.

Quantity Limits

UHC may impose quantity limits aligned with FDA dosing: 60 tablets per 30 days for the standard 5 mg twice-daily dose, or 60 tablets of the 2.5 mg dose for patients meeting dose-reduction criteria (age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher) [1]. Requests exceeding these quantities require clinical justification.